Gilead Sciences developed Yeytuo for HIV prevention, which received authorization from the European Commission following EMA assessment.
2 reports, 2 independent
Updated Aug 26
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gilead Sciences developed Yeytuo for HIV prevention, which received authorization from the European Commission following EMA assessment.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
-
European Commission
executive branch of the European Union
Coverage
Newest first; wire copies grouped- Pharmaceutical TechnologyGilead’s Yeytuo approved in EU, boosting its blockbuster potential The European Commission (EC) has approved Gilead’s Yeytuo (lenacapavir) for the prevention of HIV infection, consolidating the injec
- Business WireEuropean Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention – Yeytuo® is the First and Only European Commission (EC)-Authorized HIV PrEP Option Offering 6 Months of Protectio